{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273266","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.790777+00:00","generated_at":"2026-05-16T22:13:43.027425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access","bullets":["France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.","BOT/BAL shows 42% two-year OS, 20.9-month median OS in 123 heavily pretreated MSS mCRC patients.","Phase 3 BATTMAN trial initiated Q4 2025 across 100+ sites in Canada, France, Australia, NZ.","MiNK deconsolidation generates ~$100.9M gain; net income for Q3 and nine-month periods.","Zydus provides $10M bridge facility ahead of $91M closing; equity at $7.50/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273266","json":"https://secwatch.observer/filing/0001193125-25-273266.json","markdown":"https://secwatch.observer/filing/0001193125-25-273266.md","text":"https://secwatch.observer/filing/0001193125-25-273266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/0001193125-25-273266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/agen-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:13:43.027425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}